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Abstract
Background: The delivery of DNA into human cells has been the basis of advances in the understanding of gene
function and the development of genetic therapies. Numerous chemical and physical approaches have been used
to deliver the DNA, but their efficacy has been variable and is highly dependent on the cell type to be transfected.
Results: Studies were undertaken to evaluate and compare the transfection efficacy of several chemical reagents
to that of the electroporation/nucleofection system using both adherent cells (primary and transformed airway
epithelial cells and primary fibroblasts as well as embryonic stem cells) and cells in suspension (primary
hematopoietic stem/progenitor cells and lymphoblasts). With the exception of HEK 293 cell transfection,
nucleofection proved to be less toxic and more efficient at effectively delivering DNA into the cells as determined
by cell proliferation and GFP expression, respectively. Lipofectamine and nucleofection of HEK 293 were essentially
equivalent in terms of toxicity and efficiency. Transient transfection efficiency in all the cell systems ranged from
40%-90%, with minimal toxicity and no apparent species specificity. Differences in efficiency and toxicity were cell
type/system specific.
Conclusions: In general, the Amaxa electroporation/nucleofection system appears superior to other chemical
systems. However, there are cell-type and species specific differences that need to be evaluated empirically to
optimize the conditions for transfection efficiency and cell survival.
Background
Numerous chemical and physical methods have been
used to introduce DNA expression vectors into mam-
malian cells both in vitro and in vivo, including, but not
limited to, calcium phosphate precipitation, microinjec-
tion, electroporation, receptor-mediated gene transfer,
particle guns, viral vectors, polyfection and lipofection
[1].
The use of cationic liposome/DNA complexes (lipo-
plexes) and cationic polymers/DNA (polyplexes) for the
transfer of genes into somatic cells has become very
popular due to its limited toxicity and relative effective-
ness in vitro. The ionic interaction between cationic
lipids and DNA leads to the formation of lipoplexes that
are generally slightly cationic. The resulting DNA/lipid
complexes fuse with the anionic cytoplasmic membrane
and/or are introduced into the cells via an endocytic
pathway [2]. The delivery of the DNA into the nucleus
is still not fully understood. While transfection with
cationic lipids and polymers offers some advantages
over viral transduction, such as simplicity of production,
low toxicity, and low immunogenicity; it has yet to
reach the levels observed with viral transduction.
Furthermore, the adherence of the cationic complexes
to the nucleic acid can interfere with its accessibility to
enzymes required for processing the DNA [3].
One of the most effective and accessible physical
transfection methods, electroporation (also known as
electrotransfer, electropermeabilization, or nucleofec-
tion), involves the application of brief electric pulses to
cells or tissues to increase the permeability of cells to
macromolecules [1,4]. The recent development of the
nucleofection system has been a significant advance
* Correspondence: dieter@cpmcri.org
1California Pacific Medical Center Research Institute, San Francisco, CA, USA
Maurisse et al. BMC Biotechnology 2010, 10:9
http://www.biomedcentral.com/1472-6750/10/9
© 2010 Maurisse et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.over standard electroporation systems that have been
limited by high toxicity and a requirement for large
numbers of cells. A number of cell lines have already
been tested for their compatibility with the nucleofec-
tion system [5-12]. However, there have been no sys-
tematic studies comparing nucleofection to chemical
transfection systems in various cell types across species.
In this study, chemical reagent-mediated transfection
was compared to nucleofection using a number of pri-
mary and immortalized cell systems in three different
mammalian species (human, rabbit, and pig) to evaluate
the efficiency and toxicity. The results presented here
indicate that nucleofection is more effective than chemi-
cal transfection reagents from several different cationic
categories (dendrimer, polyethylenimine, lipid) at deli-
vering DNA into a variety of different cell types. These
studies also provided useful insight into transfection
optimization conditions and relative cell viability for the
various cells tested.
Previous studies indicated that the ratio of DNA to
lipid is an important variable that determines the effi-
ciency of transfection and the cellular toxicity [1,13]. To
evaluate the effect of varying the ratio of DNA to trans-
fection reagent, the cells were transfected with a con-
stant quantity of plasmid DNA in a complex with a
variable amount of a given transfection reagent. One to
three different DNA/reagent ratios were evaluated for
each cell system. In each case, the optimum charge ratio
for a given reagent was used for the comparison with
nucleofection. The nucleofection buffer and program are
critical parameters for nucleofection, so different pro-
grams and buffers were tested to obtain the optimal
transfection efficiency.
Methods
Cells and Culture Conditions
Adherent Cells
Primary embryonic pig fibroblasts (P16) (obtained from
Dr José Cibelli, Michigan State University, East Lansing,
MI) and embryonic rabbit ear fibroblasts (REF)
(obtained from Dr Fuliang Du, University of Connecti-
cut, Storrs, CT) [14] were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 15% or
10%, respectively, fetal calf serum (FCS, Hyclone), 2-
mercaptoethanol (1.5%), and glutamine (2 mM). Sickle
cell disease (SCD) transgenic mouse embryonic stem
cells (MESCs) containing a YAC carrying 240 kB of the
b
S-globin locus (obtained from Dr YW Kan, University
of California, San Francisco, CA) were grown on gelatin
coated plates on a mitomycin C inactivated SNL mouse
embryo fibroblast feeder layer expressing leukemia inhi-
bitory factor (LIF) in DMEM containing and 15% FCS
(Hyclone), 2 mM glutamine (Invitrogen), 10
-4 Mn o n -
essential amino acids (Invitrogen), 10
4 M2 -
mecaptoethanol (Sigma-Aldrich) [15]. Immortalized
human bronchial epithelial cells (16HBE14o- [16,17]
and CFBE41o- [18-20]) cells and the adenovirus 5
immortalized human embryo kidney cell line, HEK 293
[21], (American Type Tissue Culture Collection, Mana-
ssas, VA) were grown on tissue culture plastic coated
with an extra-cellular matrix cocktail comprised of
human fibronectin (FN) (BD laboratories, NJ), Vitrogen
(V) (BD laboratories), and bovine serum albumin (BSA)
(Biosource/Biofluids, Camarillo, CA) (FN/V/BSA) in
Minimum Essential Medium (MEM) supplemented with
10% FCS, 1% (v/v) glutamine, 1% pen/strep [22]. Pri-
mary pig and human tracheal epithelial (PTE and HTE,
respectively) cells (obtained from Dr J H Widdicombe,
University of California, Davis, CA and Dr W E Finkbei-
ner, University of California, San Francisco, CA) were
grown in modified LHC8e medium (MLHC8e): LHC8
medium (Biosource/Biofluids) supplemented with 2 mM
glutamine, 1 ml Stock 4 solution (Biosource/Biofluids), 2
μg/ml insulin (Biosource/Biofluids), 1 ml Trace Ele-
ments solution (Biosource/Biofluids), and epinephrine
(0.5 μg/ml) (Biosource/Biofluids) [22]. All cells were
grown at 37°C in humidified air containing 5% CO2 and
subcultured every 2-3 days by trypsinization.
Non-adherent Cells
SC1 lymphoblasts (American Type Tissue Culture Col-
lection, Manassas, VA, ATCC#CRL-8756) were homozy-
gous for the sickle cell allele) and LT1-1B1 human
lymphoblasts with a G>C substitution mutation in exon
3i nHPRT1 gene (codon 51) [23]. SC1 cells were grown
in suspension culture in RPMI 1640 medium supple-
mented with 20% Fetal Calf Serum (ATCC) with routine
media changes every 48 h. LT1-1B1 cells were also
grown in RPMI 1640 medium but supplemented with
10% FBS (Sigma, St Louis, MO), 5 mM L-glutamine, 40
mM HEPES, and 10 mM 6-thioguanine (6TG) (Sigma,
company info). Hematopoietic CD34
+ cells were isolated
from human fetal liver (obtained from Dr M Meunch,
University of California, San Francisco, CA) and grown
as described previously [24] in serum-free culture med-
ium consisting of Iscove’s modified Dulbecco’sm e d i u m
(IMDM) (Sigma Chemical, St. Louis, MO) supplemented
with 7.5 10-5 a-thioglycerol (Sigma Chemical), 50 μg/ml
gentamicin, 2% fraction-V ethanol-extracted BSA (Boeh-
ringer Mannheim Biochemicals, Indianapolis, Indiana,
USA), 200 μg/ml human iron-saturated transferrin
(Boehringer Mannheim Biochemicals), 10 μg/ml recom-
binant human insulin (Boehringer Mannheim Biochem-
icals), and 20 μg protein/ml human low density
lipoprotein (Sigma Chemical), 10 U/ml erythropoietin
(Amgen, Thousand Oaks, CA), and 50 ng/ml c-kit
ligand (KL) (R&D Systems Inc., Minneapolis, MN). Cells
were grown under humidified conditions in 5% CO2
with media changes every 48 h.
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IACUC approvals at the institutions where they were gen-
erated. The human samples were obtained in accordance
with the Helsinki Declaration http://www.wma.net/en/
30publications/10policies/b3/index.html from autopsy
material with informed consent when samples had identi-
fiable markers. When samples were anonymous, informed
consent was not required for autopsy materials or dis-
carded tissue. Human fetal livers were obtained from mid-
gestation fetuses after maternal consent from elective
abortions. Research with fetal tissue and human tracheal
epithelial cells obtained from autopsy were performed
with approval of the Committee of Human Research at
the University of California, San Francisco under approvals
H8858-18760-04/05 and H493-27303-04, respectively.
Nucleofection
In the electroporation (nucleofection) experiments, 1 - 2
×1 0
6 cells were resuspended in 100 μl of transfection
buffer (Table 1). The pmaxGFP plasmid (AMAXA Bio-
systems, Gaithersburg, MD) that contains an enhanced
green fluorescent protein (EGFP) gene under regulation
of a cytomegalovirus (CMV) enhancer/promoter ele-
ment and is kanamycin resistant, was then added (2 μg/
transfection sample) to the cell suspension. The cell/
DNA mixtures, in 1 cm transfection cuvettes, were
nucleoporated according to as p e c i f i cp r e d e f i n e dp r o -
gram. Following the electroporation, the cells were incu-
bated in their respective culture medium pre-heated to
37°C for 10 min, and then seeded into cell type-specific
growth medium. Unless otherwise indicated all nucleo-
fection experiments were carried out in triplicate using
3 separate dishes for each point.
The MESCs were separated from the SNL feeder cells
by short-term (30 min) plating of the trypsinized mixed
cell population in Petri dishes not coated with gelatin.
The SNL fibroblasts preferentially adhere and the
MESCs are readily harvested for nucleofection.
Transfection with Chemical Reagents
Before transfection 3 - 5 × 10
5 cells were seeded into
individual wells of 6 well plates. After a 24 h incubation
in growth medium, the cells were exposed to the poly-
plexes or lipoplexes that each contained 2 μg pmaxGFP
plasmid/well of cells. Each transfection was carried out
in triplicate and repeated 2 to 3 times. Following trans-
fection the cells were incubated at 37°C in humidified-
air (5% CO2) for 2 h. The transfection medium was
then removed and the cells were incubated for an addi-
tional 48 h in complete medium (2 ml per well).
Lipofectamine 2000 and Lipofectamine Plus
Plasmid DNA and Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) were diluted in two independent 250 μl
volumes of Opti-MEM reduced serum medium (Invitro-
gen) without serum and mixed gently. For Lipofecta-
mine Plus transfections, the DNA was pre-incubated
with 4 μl of Plus reagent and Opti-MEM to a final
volume of 25 μl. After a 5 min incubation at room tem-
perature, the DNA and the Lipofectamine 2000 in Opti-
MEM were combined and incubated for an additional
20 min at room temperature to allow the DNA-Lipofec-
tamine 2000 complexes to form. The DNA- Plus mix
(25 μl) was added to an equal volume the Lipofectamine
2000 reagent mixed with Opti-MEM and incubated for
an additional 30 min at room temperature. The DNA-
Lipofectamine 2000 complexes were then added to each
well containing cells and medium. The vol/wt ratios of
Lipofectamine 2000/DNA were: 3/1, 5/1 and 7/1, and 1/
1 for Lipofectamine Plus/DNA.
Polyethylenimine (PEI)
PEI (QBiogene, Morgan Irvine, CA) and plasmid DNA
were each diluted with equal volumes of 150 mM NaCl.
The DNA solution was then added to the PEI solution,
and after a 20 min incubation at room temperature, 200
μl/well aliquots of the DNA-PEI complexes were added
to cells grown in serum containing medium in
Table 1 Cells and Optimal Nucleofection Conditions
Species Cell name Cell description AMAXA program AMAXA buffer
Pig P16 Pig Fetal Fibroblasts U-20 NHDF
PTE Primary Pig Tracheal Epithelial Cells T-20 Basic epithelial cell
Human 16HBE41o- Immortalized Human Bronchial Epithelial cell Line (WT) O-17 V
CFBE41o- Immortalized Human CF Bronchial Epithelial Cell Line (ΔF508/ΔF508)) O-17 V
HTE Primary Human Tracheal Epithelial Cells T-20 Basic epithelial cell
LT1-1B1 Immortalized Human Lymphoblasts (HPRT mutant) G-16 T
SC-1 Immortalized Human Lymphoblasts (b
S-globin mutant) G-16 T
HSPC Primary Hematopoietic Stem/Progenitor Cells (CD34+ lin-) U-08 CD34+
HEK 293 Adenovirus immortalized human embryonic kidney cells X-01 V
Rabbit REF Rabbit Ear Fibroblasts U-23 NHDF
Mouse MESC Transgenic mouse embryonic stem cells (b
S-globin mutant) A-24 Mouse ES cell
The table contains the cells used in the studies and their origin. For each cell line/type, the optimal nucleofection program and buffer are indicated.
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residues/DNA phosphates were: 3/1, 5/1 and 8/1
Effectene
Effectene transfections were conducted according to the
manufacturer’s instructions (Qiagen, Valencia, CA). The
vol/wt ratios of Effectene/DNA were 10/1 and 25/1.
Analysis of transfected cells
Cells were harvested 48 h post-transfection, washed, and
resuspended in PBS. In adherent cell cultures, only cells
adhering to the culture dish before trypsinization were
counted as viable. Cells in suspension were exposed to
PBS containing 0.02% EGTA and 1 μg/ml propidium
iodide to identify the nonviable cells through propidium
iodide fluorescence. The cells were then sorted by flow
cytometry, evaluated with the Cellquest software (BD
Biosciences, San Jose, CA) to determine the proportion
of fluorescent cells.
The cells were transfected with a reporter plasmid
encoding the EGFP using either nucleofection or four
different chemical reagents (Effectene, Lipofectamine
2000, Lipofectamine Plus and PEI). Transfection effi-
ciency was determined 48 h after transfection as the:
(# ) /( # ). of EGFP positive cells total of cells transfected
aa
The percent cytotoxicity following transfection was:
() / ( ) CBC T −×= 100
Where B = the # of adherent or total # of cells when
grown in suspension, in the transfected sample at the
time of harvest, C = # of nontransfected adherent or
total # of cells when grown in suspension, present at the
time of harvest, and T is toxicity.
Cell viability is therefore the number of viable trans-
fected cells present at the 48 h post-transfection harvest
time compared to control, non-transfected cells, i.e., the
percent viability (V) is:
V T =− 100 .
This proportion of live cells present at the time of
harvest was taken to be an indicator of relative cell cyto-
toxicity and consequently, the cell viability following
transfection.
Results
Nucleofection
Pig and Rabbit Fetal Fibroblasts
The ability to generate transgenic animals through
somatic cell nuclear transfer (SCNT) has opened up
many possibilities for the study of disease and the devel-
opment of therapies [25]. Pig fetal fibroblasts (P16) pre-
viously used for SCNT (J Cibelli, personal
communication) were transfected using 30 different
nucleofection programs in combination with the
AMAXA NHDF buffer to determine the optimal para-
meters for nucleofection. Program U-20 was the most
effective and resulted in a 90% efficiency of GFP expres-
sion and 5% cytotoxicity (Figure 1). The most effective
program/buffer combination for rabbit embryo fibro-
blasts (REF) transfection was program U-23 with the
NHDF buffer (Table 1). After 48 h, GFP expression was
observed in 38% of the cells (Figure 1).
Human and Pig Primary Tracheal Epithelial cells
Primary airway epithelial cells play a crucial role in the
study of airway disease and infection. The ability to effi-
ciently transfer of genes into these cells is critical in
evaluating the mechanisms underlying airway epithelial
cell function and airway disease pathology. Because
there was no optimized protocol available for nucleofec-
tion of primary human or pig tracheal epithelial cells, 3
different buffers were tested (EP-39, EP-42 and E-58
(Basic Epithelial Cell buffer)). Optimization of the
human tracheal epithelial (HTE) cells involved pairing
each buffer with 9 different programs. The optimal
transfection efficiency was achieved using program T-20
and the Amaxa Basic Epithelial Cell buffer and resulted
in 47% expression efficiency and 83% cytotoxicity (17%
viability) (Figure 1, Table 1).
Nucleofection of primary pig tracheal epithelial (PTE)
cells under the same conditions, i.e., using the same buf-
fer and program, gave a transfection efficiency of 90%.
The 5% cytotoxicity (95% viability) of the transfected
PTE cells detected 48 h after transfection was consider-
ably less than that observed with the HTE cells (Figure
1)
Human Bronchial Epithelial Cell Lines
Immortalized bronchial epithelial cells [26-28] were stu-
died, because they are routinely used as models of cystic
fibrosis (CF) and airway disease. Normal, 16HBE14o-
[16], and CF, CFBE41o- [17-20], cell lines were opti-
mally transfected with buffer V and program O-17
(Table 1). The 16HBE14o- cells showed a 62% viability
and 65% transfection efficiency, while transfection of the
CFBE41o- cells gave 81% expression efficiency at 50%
viability (Figure 1).
Hematopoietic Stem/Progenitor Cells
Hematopoietic stem/progenitor cells (HSPCs) are attrac-
tive targets for gene delivery and therapy because of
their potential for self-renewal and multilineage differen-
tiation [29,30]. These properties make them ideally sui-
ted for ex vivo gene transfer that could result in a
treatment for numerous inherited and/or hematologic
disorders.
HSPCs isolated from fetal liver [24] were nucleofected
using Amaxa CD34 buffer and program U-08 (Table 1).
GFP was expressed in 55% of the HSPCs accompanied
by a viability of 50%. Furthermore, the ability of the
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after transfection when the cells were grown in differen-
tiating medium (R Maurisse and DC Gruenert, unpub-
lished data).
Lymphoblasts
Epstein-Barr virus (EBV) transformed lymphocytes (lym-
phoblasts) were nucleofected with buffer T and program
G-16 (Table 1). The transfection efficiency of two differ-
ent lymphoblast lines (SC-1 and LT1-1B1) was 75% with
an 80% viability (Figure 1).
Mouse Embryonic Stem Cells
Transgenic mouse embryonic stem cells (MESCs) that
contain a YAC that carries 240-kb b
S-globin gene family
[15] were optimally transfected using the Amaxa MESC
buffer with program A-24 (Table 1). The transfection
efficiency and viability was 62% and 66%, respectively
(Figure 1). The cells were not effectively transfected
using chemical reagents due to high cytotoxicity and/or
senescence following reagent exposure (H Emamekhoo
and DC Gruenert, unpublished observations).
HEK 293 Cells
The HEK 293 (human embryonic kidney) cell lines was
nucleofected with Amaxa buffer V and program X-01
(Table 1). The efficiency of transfection and the viability
were 93% and 72%, respectively (Figure 1).
Nucleofection vs Chemical Transfection
A number of chemical reagents were used to transfect 5
×1 0
5 cells with 2 μg of pmaxGFP plasmid. The trans-
fection efficiencies and the viabilities were then
compared to those observed for nucleofection of the
same cell lines/types (Figure 2). The quantity of plasmid
per cell transfected with the chemical transfection
reagent was two-fold more than that used for nucleofec-
tion. For each reagents one to three reagent/DNA ratios
were tested either as a ratio of vol/wt (μlr e a g e n t s / μg
DNA); Effectene: 10/1 and 25/1; Lipofectamine 2000: 3/
1, 5/1 and 7/1; Lipofectamine Plus 1/1. The reagent/
DNA ratios evaluated for PEI were based on positive
and negative charges. The charge ratios (Nitrogen resi-
dues/Phosphate) evaluated was: 3/1, 5/1 and 8/1 PEI.
Only the optimal, i.e., in terms of transfection effi-
ciency, reagent/DNA ratios were compared (Figure 2).
The data presented compares the relative effectiveness
of plasmid delivery into pig fetal fibroblast (P16) as well
as primary human and pig tracheal epithelial cells (HTE
and PTE, respectively) by chemical reagents and
nucleofection.
Pig Fetal Fibroblasts
P16 cells were transfected with 2 μg of pmaxGFP plas-
mid. The transfection efficiencies were 18% (Effectene
25/1), 28% (Lipofectamine 2000; 7/1), 20% (Lipofecta-
mine Plus) and 32% (PEI; 3/1) (Figure 2-A). Transfec-
tion by nucleofection gave an efficiency of 85%.
Pig Tracheal Epithelial Cells
PTE were transfected with 2 μg pmaxGFP plasmid in a
complex with Effectene, Lipofectamine 2000, Lipofecta-
mine Plus and PEI (Figure 2-B). The transfection effi-
ciencies of the PTE cells were 5% (Effectene; 25/1), 30%
Figure 1 The transfection efficiency obtained 48 hours after nucleofection of 10
6 cells with 2 μg of pmaxGFP plasmid. The cells are
described in Table 1. The error bars represent the standard error of the mean (SEM), with n = 3.
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10% (PEI; 3/1) transfection respectively at the ratio indi-
cated (Figure 2). The nucleofection resulted in a trans-
fection efficiency of 90% and cytotoxicity of 5%.
Human Tracheal Epithelial Cells
HTE cells were transfected with the four reagents indi-
cated below and by nucleofection (Figure 2-C). The
transfection efficiencies obtained were: 37% (Effectene;
25/1), 14% (Lipofectamine 2000; 7/1), 3% (Lipofectamine
Plus; 1/1), and 8% (PEI; 3/1), respectively (Figure 2C).
Nucleofection gave a transfection efficiency of 45%.
HEK 293 Cells
The transfection efficiency and viability with Lipofecta-
mine 2000 was 98% and 67%, respectively. The transfec-
tion efficiency with Lipofectamine Plus was 82% with a
viability of 80% (data not shown).
Figure 2 Comparison of the transfection efficacy of pmaxGFP with chemical reagents (Effectene, Lipofectamine 2000, Lipofectamine
Plus, and PEI) and nucleofection. The vol/wt ratios (μl reagent/μg DNA) for Effectene and Lipofectamine 2000 transfection and the (+/-)
charge ratios (PEI nitrogen residues/DNA phosphates) for PEI transfection are indicated in parentheses. Transfection efficacy is indicated by the
black bar, and the relative number of adherent cells in the transfected cells was compared to the number in nontransfected control cultures is
indicated by the white bar for (A) pig fetal fibroblast (P16), (B) primary pig tracheal epithelial (PTE) cells, and (C) primary human tracheal
epithelial (HTE) cells. The error bars reflect the standard error of the mean (SEM), with n = 3.
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The delivery of genes into primary and immortalized
cell lines is an underpinning of mammalian molecular
biology and has become increasingly important in bio-
medical research and therapeutic development. Defining
the parameters necessary for transfection optimization
is, thus a critical element in further enhancing gene
delivery efficacy in a wide range of cells. While there
has been significant work done in the development of
chemical and viral reagents for the delivery of recombi-
nant DNA, only limited improvements have been made
in physical delivery systems [1]. The development of a
novel electroporation system by AMAXA has shown
considerable promise as a system for delivering DNA to
a broad range of cell lines and cell systems that grow
either as adherent monolayers or in suspension
[7,31-34]. A number of cell lines from human and ani-
mals that have been particularly important for charac-
terization of airway diseases such as cystic fibrosis and
asthma, for somatic cell nuclear transfer, for the study
of hematopoietic diseases, and for mutation analysis
were evaluated and compared for their ability to be effi-
caciously transfected with the nucleofection system.
With the exception of HEK293 cells, when compared to
chemical DNA delivery vehicles, nucleofection appears
to be, in general, more effective and less toxic. The
transfection efficiency and toxicity is equivalent follow-
ing nucleofection or Lipofectamine transfection of
HEK293 cells (Figure 1).
Transfection of two immortalized human airway
epithelial cell lines, 16HBE14o- and CFB41o- and pri-
mary airway epithelial cells from pig and human (PTE
and HTE, respectively) showed that nucleofection was
more effective than the four chemical reagents tested
with the exception of the HTE cells that were also effec-
tively transfectable with Effectene. Primary human air-
way epithelial cells were difficult to transfect even by
nucleofection (45%) when compared to the PTE (95%).
While the reason for this difference is not certain, it is
possible that cells at different passages or in different
stages of differentiation will have varying responses to
insult. Additional studies will need to be undertaken to
determine whether the transfection efficiency and viabi-
lity following nucleofection can be further enhanced.
The development of somatic cell nuclear transfer
using fetal fibroblast as donor cells has played a central
role in the cloning of animals such as the pig and the
rabbit [14,35-37]. Greater than 95% of the P16 cells
expressed GFP following nucleofection while the rabbit
ear fibroblasts (REF) appeared to be more recalcitrant to
transfection and gave a GFP expression frequency in the
range of 40%. This difference may be due to species-spe-
cific factors that affect the transport and/or of
expression the plasmid DNA in the cell nucleus. In
addition, differences in the age of the cultured cells, and
cell density may also play a factor. These elements need
to be considered when optimizing transfection condi-
tions and should be addressed empirically.
Suspension cultures of hematopoietic origin have been
notoriously difficult to transfect with chemical reagents
and have had to rely on viral vector systems to facilitate
DNA delivery [1]. However, the studies here showed
that nucleofection was able to transfect both primary
human hematopoietic stem/progenitor cells as well as
immortalized lymphoblasts giving levels GFP expression
in the range of 60-80% with relatively low levels of cyto-
toxicity. Thus, nucleofection may be an effective means
of ex vivo genetic modification of hematopoietic stem
cells that have multilineage potential.
Embryonic stem (ES) cells have become increasingly
more important due their potential for organ regenera-
tion and for the development of models to study disease.
Mouse ES cells (MESCs) have been notoriously difficult
to transfect with chemical reagents, and have thus been
relegated to transfection by electroporation. Standard
electroporation protocols have resulted in high levels of
cytotoxicity that have undermined the ability to transfer
genes into the cells and the potential of the MESCs to
produce viable embryos or differentiate in a lineage
directed fashion. The nucleofection system has provided
the opportunity to overcome some of these issues by
enhancing transfection efficacy and MESC viability. As
indicated by the studies presented here, MESCs can be
routinely transfected at efficiencies of about 60% with a
concurrent 60% viability. These observations have
important implications for the transfection of human ES
cells and for their genetic modification and directed dif-
ferentiation in that nucleofection has the potential of
producing genetically modified cells that can be pheno-
typically manipulated without losing their pluripotency.
Conclusion
This study demonstrates the nucleofection system is
effective for a broad range of cell lines and cell types,
resulting in high levels of transgene expression and low
toxicity. Not only is it superior when compared to var-
ious commercially available chemical DNA delivery
vehicles in terms of transfection efficacy and viability, it
also has potential therapeutic applications in ex vivo
gene delivery.
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epithelial; REF: rabbit embryo fibroblasts; SCD: sickle cell disease; 6-TG: 6
thioguanine; YAC: yeast artificial chromosome.
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